Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery

被引:87
作者
Bouzin, Caroline [1 ]
Feron, Olivier [1 ]
机构
[1] UCL FATH 5349, Univ Pharmacol & Therapeut, B-1200 Brussels, Belgium
关键词
tumor vasculature; angiogenesis; interstitial fluid pressure; tumor blood flow heterogeneities; tumor-associated fibroblasts; tumor-associated macrophages; anti-angiogenic; vascular-disrupting agents; caveolae; transcytosis;
D O I
10.1016/j.drup.2007.03.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The identification of a critical role of tumour stroma in the regulation of tumour interstitial fluid pressure and the simultaneous discovery of the impact of anti-angiogenic drugs on tumour hemodynamics have provided new potential for improving tumour delivery of anti-cancer drugs. Here, we review the most recent studies investigating how tumour-associated fibroblasts and macrophages as well as the extracellular matrix itself may be targeted to facilitate delivery of both low-molecular weight drugs and macromolecules. In addition, we summarize the current understanding of the use of vasoactive compounds, radiotherapy and vascular-disrupting agents as potential adjuvants to maximize tumour delivery of anti-cancer drugs. The impact of these strategies on the diffusive and convective modes of drug transport is discussed in the light of Fick's and Starling's laws. Finally, we discuss how transcytosis through caveolae may also be exploited to optimize the selective delivery of conventional chemotherapy the subendothelial tumour cell compartment. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:109 / 120
页数:12
相关论文
共 73 条
[1]   Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: Association between caveolin-1 expression and ABI-007 [J].
Altundag, Kadri ;
Bulut, Nilufer ;
Dizdar, Omer ;
Harputluoglu, Hakan .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) :329-330
[2]   Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy [J].
Baranowska-Kortylewicz, J ;
Abe, M ;
Pietras, K ;
Kortylewicz, ZP ;
Kurizaki, T ;
Nearman, J ;
Paulsson, J ;
Mosley, RL ;
Enke, CA ;
Östman, A .
CANCER RESEARCH, 2005, 65 (17) :7824-7831
[3]   Emerging role of platelet-derived growth factor receptor-β inhibition in radioimmunotherapy of experimental pancreatic cancer [J].
Baranowska-Kortylewicz, Janina ;
Abe, Michio ;
Nearman, Jessica ;
Enke, Charles A. .
CLINICAL CANCER RESEARCH, 2007, 13 (01) :299-306
[4]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[5]   Vascular remodeling and clinical resistance to antiangiogenic cancer therapy [J].
Bender, JG ;
Cooney, EM ;
Kandel, JJ ;
Yamashiro, DJ .
DRUG RESISTANCE UPDATES, 2004, 7 (4-5) :289-300
[6]   Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics [J].
Board, R ;
Jayson, GC .
DRUG RESISTANCE UPDATES, 2005, 8 (1-2) :75-83
[7]   Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin [J].
Bredow, S ;
Lewin, M ;
Hofmann, B ;
Marecos, E ;
Weissleder, R .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (05) :675-681
[8]  
Brekken C, 2000, ANTICANCER RES, V20, P3513
[9]   Caveolae: Mining little caves for new cancer targets [J].
Carver, LA ;
Schnitzer, JE .
NATURE REVIEWS CANCER, 2003, 3 (08) :571-581
[10]   The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines:: potential for selective tumour blood flow modification [J].
Cemazar, M ;
Wilson, I ;
Prise, VE ;
Bell, KM ;
Hill, SA ;
Tozer, GM .
BRITISH JOURNAL OF CANCER, 2005, 93 (01) :98-106